Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGD013 + brivanib alaninate
- Development stage
- Unknown
- Lead developer
- Zai Lab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
MGD013 (tebotelimab) + brivanib alaninate is an investigational combination therapy studied primarily for advanced liver cancers, including hepatocellular carcinoma (HCC). MGD013, also known as tebotelimab, is a bispecific DART® monoclonal antibody that targets and blocks both PD-1 and LAG-3 immune checkpoint molecules to restore or sustain T-cell function in cancer immunotherapy. Brivanib alaninate (BMS-582664) is an oral small molecule multitargeted tyrosine kinase inhibitor that antagonizes VEGFR2 and FGFR1, key pathways involved in tumor angiogenesis and growth. The combination aims to enhance anti-tumor activity by simultaneously modulating immune checkpoints and inhibiting tumor angiogenesis. The drugs have been evaluated together in phase 1/2 clinical trials for advanced HCC, including patients who have failed prior immune checkpoint inhibitor therapy[1][4][6][8].
- Other names
- ZL-2301ZL2301ZL 2301
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on MGD013 + brivanib alaninate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGD013 + brivanib alaninate.